All studies involving C57BLKS/J


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackert1 body size and weight Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Ackert1 DXA Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Albers1 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). inbred   (15) both 6-14wks 1999
Albers1 protein activity assessment
with high-fat diet 		Phospholipid transfer protein activity. 4h fast. inbred   (15) both 6-14wks 1999
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. inbred w/CC8   (58) both 6wks 2013
Benoist1 immune cell quantification Regulatory T cells (Treg), thymus, spleen. inbred   (33) m 5-6wks 2007
Berndt1 ventilator
with methacholine 		Airway resistance. Baseline vs. methacholine-challenged (several doses). inbred   (37) both 9-12wks 2010
Berndt2 plethysmography
with methacholine 		Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt2 ventilator
with methacholine 		Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt3 metabolite quantification Vitamin D concentration (serum). inbred   (18) m 11wks 2011
Berndt4 histopathology Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. inbred   (28) both 87wks 2011
Brugnara1 complete blood count Hematology. inbred   (10) both 8wks 2013
Brugnara1 ion transport assessment Hematology red cell ion content, ion transport. inbred   (10) both 8wks 2013
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. inbred   (142) m 2014
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. inbred   (38) both 8-10wks 2011
Crowley1 behavior observation
with haloperidol 		Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol 		Baseline vs. after haloperidol 60d implant. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol 		Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol 		Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol 		Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. inbred w/CC8   (27) m 9-28wks 2012
CSNA01 body weight
with sucrose 		Effect on body weight of several days in a lever-based oral sucrose self-administering system. HMDP   (91) m 7-22wks 2018
CSNA01 operant conditioning chamber
with sucrose 		Rewards behavior and learning in a lever-based oral sucrose self-administering system. Daily 8 h sessions for 3 days. HMDP   (91) m 7-22wks 2018
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. inbred w/CC7   (34) m 10wks 2012
Evsikova1 body weight Body weight inbred   (14) both 25wks 2009
Evsikova1 intake monitoring Food intake, water intake at 6mo. Light phase, dark phase, total. inbred   (14) both 25wks 2009
Evsikova1 monitoring system Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. inbred   (14) both 25wks 2009
Finn1 bottle choice test
with ethanol 		Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). inbred   (22) both 8-12wks 2007
Gros1 genotype assessment
with Candida albicans 		C5 allele sufficiency or deficiency. inbred   (36) f 8-12wks 2011
Gros1 in vitro assay
with Candida albicans 		Susceptibility to infection with Candida albicans. inbred   (36) f 8-12wks 2011
Harrill1 body weight
with isoniazid 		Body weight. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid 		Liver pathology scores. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid 		Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid 		Alanine transaminase. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid 		Body, liver, kidney weights. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289 		Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 body weight
with DB289 		DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289 		Kidney metabolite (DB75) concentration. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289 		Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289 		Kidney and liver weights. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289 		Urine volume, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation 		Bronchoalveolar cell differential after exposure to radiation (18 Gy). inbred   (26) both 15-36wks 2012
Haston1 health assessment
with radiation 		Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation 		Post exposure to radiation. inbred   (26) both 15-36wks 2012
Hawes1 ophthalmoscopy Retinal fundoscopic examination. inbred w/CC7   (41) both 6-7wks 2008
Hawes1 slit lamp Eye morphology. Frequency rates of disorders. inbred w/CC7   (41) both 6-7wks 2008
Hillebrands1 histopathology Kidney pathology at 20mo. inbred   (23) both 87wks 2014
Jax2 MHC haplotype tissue typing Major histocompatibility complex (MHC) H2 haplotype. inbred   (56) both 2000
Jax3 colony observation Reproductive performance. inbred   (33) f various 1991
Jax4 colony observation Appearance, coat color inbred   (61) both 2006
Jax5 colony observation Reproductive performance. inbred   (35) f various 2009
Johnson1 ABR test Auditory brainstem response. inbred   (51) both 3-12wks and 15-72wks 2000
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. inbred   (30) both 52, 78, 104 wks 2008
Korstanje2 histopathology Kidney pathology. Aging study, 6mo, 12mo, 20mo. inbred   (29) m 52, 78, 104 wks 2013
Kumar2 open field test Distance traveled, after first 10 min and after 55 min. other   (58) both 7-26wks 2019
Kumar3 body weight Body weight inbred w/CC8   (62) both 8-14wks 2021
Kumar3 open field test Locomotor activity and grooming behavior. inbred w/CC8   (62) both 8-14wks 2021
Kumar4 body size and weight Body length measurements. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 gait analysis Angular velocity, Stride speed, Step length, Step width, and other gait metrics. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 open field test Distance traveled. inbred w/CC8   (62) both 10-20 wks 2021
Lightfoot1 body weight Body weight inbred   (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. inbred   (41) both 8-9wks 2010
Marchuk1 histopathology Cerebral infarct volume, stroke susceptibility. Surgical occlusion of distal medial cerebral artery (MCA) to induce ischemia. inbred   (16) both 11-13wks 2009
Massett1 body weight Body weight inbred   (34) both 8wks 2012
Massett1 treadmill endurance test Duration, distance, work. inbred   (34) both 8wks 2012
Maurer1 body weight
with atenolol, isoproterenol 		Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol 		Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol 		Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol 		Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Naggert1 body weight
with high-fat diet 		High-fat diet for 8wks. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 DXA
with high-fat diet 		Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet 		Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 metabolic panel
with high-fat diet 		Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. inbred w/CC7   (43) both 5, 21 wks 2003
Paigen1 body weight
with high-fat diet 		Baseline vs. high-fat diet for 8wks. inbred   (44) both 15-19wks 2000
Paigen1 histopathology
with high-fat diet 		Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet 		Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. inbred   (44) both 15-19wks 2000
Paigen1 organ dimensions
with high-fat diet 		Gallbladder volume after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 organ weights
with high-fat diet 		Liver weight after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen2 histopathology
with high-fat diet 		Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen2 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen3 body weight
with high-fat diet 		Baseline vs. high-fat diet for 8wks. obesity mutants   (8) both 15-19wks 2000
Paigen3 histopathology
with high-fat diet 		Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet obesity mutants   (8) both 15-19wks 2000
Paigen3 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. obesity mutants   (8) both 15-19wks 2000
Paigen3 metabolic panel
with high-fat diet 		Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. obesity mutants   (8) both 15-19wks 2000
Paigen3 organ dimensions
with high-fat diet 		Gallbladder volume after 8wks on high-fat diet obesity mutants   (8) both 15-19wks 2000
Paigen3 organ weights
with high-fat diet 		Liver weight after 8wks on high-fat diet. obesity mutants   (8) both 15-19wks 2000
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. inbred w/CC7   (43) both 10wks 2002
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Peters1 complete blood count Hematology. inbred w/CC7   (43) both 10wks 2001
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (30) both 26, 52, 78, 104 wks 2007
Petkova1 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Pletcher1 body weight Body weight inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 10 min test. inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. inbred   (32) m 7-9wks 2007
Seburn2 gait analysis Aging study, 6mo, 18mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Seburn2 grip strength Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Shimomura2 monitoring system Circadian and sleep-related behavior. inbred w/CC7   (38) both 10wks 2015
Sugiyama1 tail cuff Heart rate and blood pressure. Conscious mice. inbred   (25) m 10wks 2007
Sundberg1 study archive Histopathology. Aging study. inbred   (28) both 2008
Tarantino1 body weight
with cocaine 		Body weight inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine 		Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. inbred   (45) m 8-11wks 2015
Threadgill1 biomarker quantification
with acetaminophen 		Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen 		Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolic panel
with acetaminophen 		Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen 		Liver protein homeostasis. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen 		Liver weight after acetaminophen (several doses) vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Tordoff3 body weight Body weight inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 bottle choice test Various salt solutions (several concentrations) vs. water. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 DXA Body mass, fat mass, lean mass, bone mineral density and content. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 monitoring system Bleeding time to collect approx 30 µL. inbred w/CC7   (40) both 9-15wks 2002
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X HMDP   (248) both 2018
Vinyard1 body weight Body weight inbred   (21) both 6-8wks 2009
Vinyard1 bone dimensions Craniofacial bone dimensions. inbred   (21) both 6-8wks 2009
Willott1 acoustic startle test Acoustic startle response, prepulse inhibition. inbred w/CC7   (40) both 5-6wks 2002
Willott1 body weight Body weight inbred w/CC7   (40) both 5-6wks 2002
Wiltshire2 drug and metabolite quantification
with fluoxetine 		Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine 		Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine 		Immobility. Fluoxetine-treated vs. control. 5 min test. inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine 		Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib 		In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. inbred w/CC7   (36) m 10wks 2015
Xing1 ECG Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. inbred   (29) both 26, 52, 87 wks 2008
Xing2 gait analysis Aging study, 6mo, 12mo, 18mo. inbred   (31) both 26, 52, 78 wks 2010
Yuan1 body weight Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan2 colony observation Life span study. Survival curves. Aging study. inbred   (31) both max lifespan 2007
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. inbred   (32) both 26, 52, 78 wks 2008
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. inbred   (32) both 26, 52, 78 wks 2008
Yuan4 colony observation Observed age at vaginal opening (patency). Aging study. inbred   (33) f 2-9wks 2009
Zheng1 tympanometry Middle ear function. inbred   (61) both 15-51d 2008